BACK TO TOP

The Oncology Consortia of Criterium Global CRO

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:
   Academic GI Cancer Consortium (AGICC)
   Academic Myeloma Consortium (AMyC)
   Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)
   Academic Breast Cancer Consortium (ABRCC)

The Consortia Model utilizes translational science methodologies to streamline cancer research and development. Each member chosen for the consortia is usually located at a hospital associated with an academic institution that has superior infrastructure and staff to meet the requirements for not only translational and investigator initiated studies, but also the design and completion of all phases of clinical trials. Our model allows us to provide expertise and innovative solutions for the rapid design, implementation, management and completion of complex cancer trials. Read more on the Consortia model for progressive research.


“It’s very appropriate that ASCO recognizes Ross Camidge as one of the ‘go-to experts’ at the cutting edge of translational research in thoracic oncology. It is because of Ross’s recognized expertise that sponsors working with ATOMIC not only have access to superbly designed and executed clinical and translational trials, but also have ongoing access to a virtual expert advisory board led by Ross.”

– John S. Macdonald, MD, Senior Medical Advisor for Criterium Inc and The Oncology Consortia of Criterium


Academic GI CANCER Consortium (AGICC)

The Academic GI Cancer Consortium (AGICC) is presently represented by Key Opinion Leaders (KOLs) and Top Investigators at 15 of the most prestigious institutions in the USA. It represents an innovative research model that brings together a world class team of institutions and investigators to design and rapidly complete clinical trials in gastrointestinal (GI) cancers.

“Today, every cancer is a “rare tumor” due to its unique molecular characteristics, requiring teams of experts with the experience and knowledge to tackle these distinct problems. AGICC is up to the challenge, carrying out cutting edge clinical trials and ultimately improving patient outcomes.” – Wells Messersmith, M.D., AGICC Director



Academic MYELOMA Consortium (AMyC)

The Academic Myeloma Cancer Consortium (AMyC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at 9 of the most prestigious institutions in the USA. It brings together an expert team of institutions and investigators to design and rapidly complete clinical trials with the ultimate goal of identifying new drugs to treat this disease.

“AMyC fills a critical need for pharmaceutical sponsors, providing an unparalleled level of strategic, scientific, and operational expertise in a timely manner.” — Brian G.M. Durie, M.D., AMyC Director



Academic THORACIC ONCOLOGY Medical Investigators Consortium (ATOMIC)

The Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at 11 of the most prestigious institutions in the USA. Our Centralized Network Model (CNM) advances the clinical trial model to be better suited to adapt to changes in rapid cancer drug development.

“ATOMIC brings together a powerful mixture of mature thought leaders and the next generation of experts with the sole goal of designing and completing clinical trials that will change the way we do business in thoracic oncology for the better.” – D. Ross Camidge, M.D., Ph.D, ATOMIC Director



Academic BREAST CANCER Consortium (ABRCC)

The Academic Breast Cancer Consortium (ABRCC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at 14 of the most prestigious institutions in the USA. It provides a platform on which to design and develop state of the art targeted and combination studies for cancer drug treatments.

“ABRCC is an academic consortium formed for the new era of clinical trial design and implementation. Our goal is to rapidly translate advances in breast cancer research into targeted therapies that will benefit our patients.” – Peter Kabos, M.D., ABRCC Director

GET TO KNOW US!

DOWNLOAD OUR BROCHURE